Louisiana is currently home to 923 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
Recruiting
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Gender:
Male
Ages:
50 years and above
Trial Updated:
01/23/2023
Locations: Lucid Investigative Site, Shreveport, Louisiana
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?
Recruiting
Purpose: It is unknown whether instillation of a drop of anesthetic ophthalmic solution into the eye such as proparacaine hydrochloride 0.5% prior to probing and irrigation of the tear duct (lacrimal drainage) system improves participant comfort during the procedure. To date, there have been no formal studies evaluating the possible benefit of this pretreatment. Methods: Participants 18 years and older who present to the Louisiana State University or associated outpatient ophthalmology clinic(s... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/15/2022
Locations: Louisiana State University Health Sciences Center, New Orleans, Louisiana
Conditions: Epiphora, Dacryostenosis, Dacryocystitis
TruGraf® Long-term Clinical Outcomes Study
Recruiting
This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months. In addition subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Tulane University Hospital and Clinic, New Orleans, Louisiana
Conditions: Kidney Transplant Rejection
StimRouter Registry Clinical Protocol
Recruiting
This Registry study will prospectively evaluate the long-term effectiveness, safety, and tolerability of the StimRouter Neuromodulation System, along with evaluating the technical performance of StimRouter, surgical outcomes, health-related quality of life, concomitant medical use, and subject's impression of improvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2022
Locations: Warner Orthopedics, Baton Rouge, Louisiana
Conditions: Chronic Pain, Peripheral Neuropathy, Nervous System Diseases, Peripheral Nervous System Diseases, Peripheral Nervous System Problem, Peripheral Nerve Injuries, Peripheral Nervous
Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)
Recruiting
A Randomized Controlled Multicenter Clinical Trial, Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) and Standard of Care versus Standard of Care alone in the healing Chronic Diabetic Foot Ulcers. Multi-center, open label, randomized controlled trial. Study is estimated to require 12 months from first subject enrolled to last subject visit.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Serena Group Baton Rouge, Baton Rouge, Louisiana
Conditions: Chronic Diabetic Foot Ulcers
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Spine Institute of Louisiana, Shreveport, Louisiana
Conditions: Symptomatic Cervical Disc Disease
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: Ochsner Benson Cancer Center, Jefferson, Louisiana
Conditions: Leukemia, Myeloid, Acute
Investigate Wound Healing, Aesthetics & Pt Satisfaction Post NAC Reconstruction Using a Decellularized Donor NAC Graft
Recruiting
To evaluate the wound healing response following nipple-areolar complex (NAC) reconstruction with a decellularized donor NAC graft (DCLNAC)
Gender:
Female
Ages:
Between 18 years and 65 years
Trial Updated:
10/13/2022
Locations: St. Charles Surgical Hospital, New Orleans, Louisiana
Conditions: Post-Mastectomy Breast Deformity (Disorder)
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Delta Research Partners, Bastrop, Louisiana
Conditions: Non Alcoholic Steatohepatitis (NASH)
REFINE Study: A Prospective Study In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of the use of Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material in fusion in patients with chronic low back pain that present with degenerative disc disease with concurrent neurogenic claudication.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/15/2022
Locations: Koga Neurosurgery, Slidell, Louisiana
Conditions: Lumbar Spinal Stenosis
Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children
Recruiting
Study to assess the diagnostic accuracy (sensitivity, specificity, positive and negative predictive value) of DBV1605 for the diagnosis of non-Immunoglobulin E (IgE) mediated cow's milk allergy (CMA) in children with symptoms suggestive of non-IgE mediated CMA.
Gender:
All
Ages:
Between 29 days and 24 months
Trial Updated:
08/09/2022
Locations: MedPharmics, LLC - Lafayette, Lafayette, Louisiana
Conditions: Cow's Milk Allergy
A Sub-Chronic Evaluation of the Safety of Celastrol in Human Subjects
Recruiting
This is an open label safety study that will not be blinded or placebo controlled. Purpose is to evaluate the safety of Celastrol in healthy men and women volunteers, between 18 and 40 years of age, over a 90-day period. Celastrol is different than Cholesterol. Cholesterol is a risk for heart disease. Celastrol is a natural occurring compound extracted from the root of Tripterygium wilfordii, a herb used in Chinese medicine.
Gender:
All
Ages:
Between 18 years and 40 years
Trial Updated:
08/08/2022
Locations: Patient Plus Urgent Care, Baton Rouge, Louisiana
Conditions: Safety